Showing results (51-60 of 131) with videos related to
Sort By:
Pageof 14
Multiple Sclerosis and Related Disorders|March 20, 2015
Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center dataSushmita Datta, Terrell D Staewen, Stacy S Cofield, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2018
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesionsColm Elliott, Jerry S Wolinsky, Stephen L Hauser, et al.Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|August 20, 2016
Limbic Pathway Correlates of Cognitive Impairment in Multiple SclerosisZafer Keser, Khader M Hasan, Benson Mwangi, et al.European Journal of Neurology|March 16, 2021
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trialsGavin Giovannoni, Ludwig Kappos, Jerome de Seze, et al.Journal of Magnetic Resonance Imaging : JMRI|May 21, 2005
Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: consensus report of the white matter study groupMassimo Filippi, Andrea Falini, Douglas L Arnold, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|August 21, 2003
Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trialsFilippo Martinelli Boneschi, Marco Rovaris, Kenneth P Johnson, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|November 13, 2018
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trialEdward J Fox, Clyde Markowitz, Angela Applebee, et al.Clinical Trials (London, England)|April 2, 2014
Recruitment of participants to a multiple sclerosis trial: the CombiRx experienceMinal J Bhanushali, Tarah Gustafson, Steve Powell, et al.Neurology(R) Neuroimmunology & Neuroinflammation|July 7, 2017
Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data setMarcus W Koch, Gary R Cutter, Gavin Giovannoni, et al.Journal of Neuroimmunology|November 26, 2018
Exploring the relationship between Endothelin-1 and peripheral inflammation in multiple sclerosisNatalia P Rocha, Gabriela D Colpo, Javiera Bravo-Alegria, et al.Pageof 14